Based on the studies reviewed, it appears that both mutations leading to elevated NRF2 expression or a lack of NRF2 are effective in lung cancer treatment, largely determined by the stage of carcinogenesis studied (i.e., early during initiation or promotion compared to metastasis)—two radically diverse findings. The gene discussed is NFE2L2; the disease is lung cancer.